Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial.
Tanaka A, Komukai S, Shibata Y, Yokoi H, Iwasaki Y, Kawasaki T, Horiuchi K, Nakao K, Ueno T, Nakashima H, Tamashiro M, Hikichi Y, Shimomura M, Tago M, Toyoda S, Inoue T, Kawaguchi A, Node K; Pioglitazone Reduce Inflammation and Restenosis with and without Drug Eluting Stent (PRIDE) Study Investigators.
Tanaka A, et al. Among authors: shibata y.
Heart Vessels. 2018 Sep;33(9):965-977. doi: 10.1007/s00380-018-1143-3. Epub 2018 Feb 27.
Heart Vessels. 2018.
PMID: 29487991
Clinical Trial.